Form 4: IOVANCE CFO Jean-Marc Bellemin Reports Routine RSU Vesting and Tax Withholding

IOVANCE Biotherapeutics' Chief Financial Officer, Jean-Marc Bellemin, reported the vesting of 8,789 restricted stock units (RSUs) and the subsequent withholding of 4,464 shares for tax purposes on June 2, 2025.

Summary

• Jean-Marc Bellemin, Chief Financial Officer of IOVANCE Biotherapeutics, Inc. (IOVA), reported transactions related to his beneficial ownership.
• On June 2, 2025, 8,789 restricted stock units (RSUs) vested, converting into common stock.
• Concurrently, 4,464 shares of common stock were withheld by the Issuer to satisfy mandatory tax withholding requirements upon the RSU vesting, which was not an open market sale.
• The price used for the tax withholding was $1.76 per share.
• Following these transactions, Mr. Bellemin beneficially owns 60,529 shares of common stock.
• Additionally, 61,528 Restricted Stock Units (RSUs) remain outstanding, which were part of a grant on March 1, 2024.

Sentiment

Score: 5

Explanation: The document reports a routine and expected executive compensation event (RSU vesting and tax withholding) which carries a neutral sentiment. It does not indicate positive or negative operational performance or strategic shifts.

Positives

• The vesting of Restricted Stock Units (RSUs) represents a scheduled compensation event for the Chief Financial Officer, indicating the realization of previously granted equity incentives.

Negatives

• A portion of the vested shares (4,464 shares) was withheld by the company to cover tax obligations, resulting in a reduction of the net shares received by the reporting person.

Risks

• No new specific risks are identified in this routine Form 4 filing beyond the general risks associated with executive compensation and equity dilution from RSU vesting, which are typically factored into a company's stock structure.

Future Outlook

The remaining 61,528 Restricted Stock Units (RSUs) held by Jean-Marc Bellemin are scheduled to vest in equal quarterly installments, indicating a predictable future compensation schedule.

Management Comments

• The filing reflects a routine compensation event for Jean-Marc Bellemin, the Chief Financial Officer, as part of his equity incentive plan.

Industry Context

This Form 4 filing details a standard executive compensation event, specifically the vesting of Restricted Stock Units (RSUs) and associated tax withholding. Such events are common practice across publicly traded companies, particularly in the biotechnology sector, as a means of aligning executive incentives with shareholder value over time.

Comparison to Industry Standards

• The vesting of RSUs and subsequent tax withholding is a standard mechanism for executive equity compensation across industries, including biotechnology.
• The reported transaction is a routine event and does not provide specific performance metrics for direct comparison to industry peers or projects. It reflects the execution of a pre-existing compensation plan.

Stakeholder Impact

• Shareholders: The vesting of RSUs is a pre-planned equity compensation event that contributes to potential minor dilution, which is typically already factored into the company's share structure and compensation plans.
• Employees: This filing pertains specifically to executive compensation and does not directly impact the broader employee base, though it reflects the company's general approach to equity incentives.

Next Steps

• The remaining 61,528 Restricted Stock Units (RSUs) will continue to vest in equal quarterly installments as per the original grant terms.

Key Dates

Keywords

IOVANCE Biotherapeutics, IOVA, Form 4, SEC filing, Insider transaction, Restricted Stock Units, RSU vesting, Executive compensation, Jean-Marc Bellemin, Stock ownership, Tax withholding